Helius Medical Technologies Overview
Valuation check: HSDT's ROE is -69.15%, below the Technology sector average of 47.89%.
Get informed when a big investor buys or sells
+ Follow-69.15%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for HSDT is -69.15%. That is below the Technology sector average of 47.89%. Investors often review this figure alongside Helius Medical Technologies's historical trend and sector peers before judging valuation or financial health.
Against Technology companies, HSDT currently prints -69.15% for ROE, while the sector average sits near 47.89%. That is roughly 244.4% below the sector mean. Large gaps often invite a closer look at Helius Medical Technologies's growth, margins, and balance sheet.
Return on Equity shows how effectively Helius Medical Technologies converts resources into returns. At -69.15%, HSDT may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting HSDT's ROE (-69.15%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Helius Medical Technologies's ROE against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.
